Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

/p>

-- Six of 9 patients in one treatment arm who completed 12 weeks of treatment, and who had achieved an RVR as defined by the study protocol ((less than)10 IU/mL), continued to have undetectable HCV RNA 20 weeks after stopping all treatment ("SVR20").

-- The treatment discontinuation rate due to adverse events through 12 weeks was 11% in telaprevir arms and 3% in the control arm. Rash, gastrointestinal events and anemia were the most common events leading to discontinuation in the telaprevir arms.

"These interim results support our approach to evaluating telaprevir-based regimens of differing durations in our Phase 2 program. The results of the 12-week duration regimen provide a level of confidence in the shorter duration approach, and we look forward to safety and antiviral data, including SVR data, from the 24-week telaprevir-based regimens," said John Alam, M.D., Executive Vice President, Medicines Development, and Chief Medical Officer of Vertex. "The information from PROVE 1 and PROVE 2 should allow us to design optimized durations and regimens for Phase 3 development."

PROVE 1 and PROVE 2 represent two of three large, ongoing clinical studies of telaprevir. In aggregrate, the three studies are designed in part to evaluate the safety and antiviral activity of different durations of telaprevir-based therapy in genotype-1 infected HCV treatment-naive and treatment-failure patients, both with and without ribavirin. Taken together, the PROVE studies are expected to provide information to optimize the treatment duration and treatment regimen for telaprevir-based therapy.

PROVE 1: Implications for Clinical Development and Registration Path

Vertex today discussed the potential implications that the new information from PROVE 1 has for future clinical development of telaprevir. Vertex stated its intention to consider evaluation of treatment regimens that would include telaprevir in combination with peg-IFN and RBV, and depending
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

Post Your Comments:
(Date:11/6/2009)... Oxygen Biotherapeutics, ...at a previously approved reverse split of its comm...on Monday, Nov. 9, 2009 on a 1-for-15 split-adjust... trade under the new symbol OXBT. The stock also w... split becomes effective. ,, "This reverse spli...
(Date:11/6/2009).... 6 Watson Pharmaceutica...ceutical company, announced today that Paul Bisaro...will provide an overview and update of the Company...hcare Conference on Wednesday, November 11, 2009 a...ntation will be webcast live and can be accessed o...
(Date:11/6/2009)...ov. 6 The ,Help is Here...ina and Georgia throughout the week of November 9-...d financially-struggling patients access informati... for free or nearly free. With the nation,s unempl...hip for Prescription Assistance (PPA) bus tour is ...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3NYCs Only Walk in Botox Clinic SmoothMED Where Boytox Hits Men Right in the Brow 21 54529 1Edifecs Launches the Edifecs5010 28TM 29 Compliance Suite of Tools Resources and Services for 5010 Migration 54526 1Edifecs Launches the Edifecs5010 28TM 29 Compliance Suite of Tools Resources and Services for 5010 Migration 54526 2Edifecs Launches the Edifecs5010 28TM 29 Compliance Suite of Tools Resources and Services for 5010 Migration 54526 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2
...s Overall Survival by 33% 3.5 Years Post Surgery, ...- CEL-SCI,CORPORATION announced today that its can...ncrease long term overall survival in a,Phase II s...re,presented on May 20, 2007 at the First Internat... Oral Oncology in Amsterdam, the,Netherlands, by D...
...INESS WIRE)--May 21, 2007 - Cougar Biotechnology,...ase I and Phase,II data on the Company,s prostate ... was presented at the American Urological,Associat...g place,in Anaheim, California. The data was prese...h UK Centre for Cancer Therapeutics at,The Institu...
Other Medicine Technology:CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 2CEL-SCI Presents Long-Term Cancer Survival Data With Multikine 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4
(Date:11/8/2009)...biopharmaceuticals to be available at the Company&... Toronto, ON (PRWEB) November 8, 2...ure Biopharma Inc. today announced that the Compan...eutical grade freeze dryer and expects to make com...able for contract manufacturing of biopharmaceutic...
(Date:11/8/2009)...e in the Western District of Pennsylvania award a ...ing for a medical malpractice case. Attorneys Tho...omas E. Crenney and Associates, LLC handled the ca...d against the Uniontown Hospital. The woman had t...t age 18. , Pittsburgh, P...
(Date:11/8/2009)...e is won," said Dr. Charmaine Yoest. ,, WASHIN...of 240-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahl...on mandates and funding in HR 3962 passed on the H... President and CEO Dr. Charmaine Yoest said, "The ...-life Americans across this country who have flood...
(Date:11/8/2009)...wire/ -- USAction this evening hailed passage of t...ill make health care more affordable for consumers...e access to health care for millions of Americans ...DR and Harry Truman would be proud," said USAction...s among our country,s proudest achievements. Today...
(Date:11/8/2009)... to Secure the Stability of Medicare ,, HOUSTO...ributable to: J. James Rohack, M.D., President, Am...www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ...th reform bill, which will help improve the health...swift passage of H.R. 3961 to secure the stability...
Breaking Medicine News(10 mins):Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
... failure patients in United States have better sho... lose that advantage over time.// Their study...ves of Internal Medicine. Heart failure is th...ne-year risk-standardized mortality rates among 28...
... office atmosphere by reducing the workload and pr...Numerous studies have already demonstrated // the ...front of the computers. A new study now reveal...led dry eye. Dry eye is an irritating, painful con...
...te (QBI) have now found a process that could lead...suffering from dementia and acquired brain injury....part of the brain commonly associated with memory ...fessor Perry Bartlett, from The University of Quee...
... over the alarming increase of spread of HIV infec...aid that Indonesia has to face the AIDS effectivel...ead of HIV in Asis has become very high as one in ...of the spread of the communicable disease AIDS is ...
...dia’s Health Minister Anbumani Ramadoss on 29 Nove... made towards achieving the Millennium Development...ed to make recommendations and suggestions, and la...ef Yogi Deveshwar, and the head of the lobby's nat...
...gists has revealed that the libido of a patient ma...ing epilepsy.// The secretion and creation of test...ble of reducing the sexual drive of the patient. ... no drugs help, which is the case for about one-qu...
Other Medicine News:Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Not Blinking Enough In Front Of The Computer Can Cause Dry Eye 2Health News:Research Targets treatment for dementia and brain injuries 2
... Drawing on over 20 years of CT engineering innova... 16 is at the forefront of the revolution in CT im... data at high speed with superb spatial resolution... clinical experience and close cooperation with le...
... The Mx8000 IDT 16 is Philips premium 16-slice CT ...are performed to automatically delivering high qua...ates a new direction in a platform that has been t...o comprehensive organ assessment literally within ...
... The TLIF Instruments are designed to facilitate d... non-structural bone graft during interbody fusion...ow easy use during TLIF, for which they were prima...effectively in PLIF and ALIF. Disc rongeurs: used ...
Pathfinder
Medicine Products: